Insights & Blog
Field notes, regulatory reads and scientific perspective from the people running our sites, our biobank and our trials.
India carries close to a fifth of the world's disease burden yet hosts fewer than two in a hundred global clinical trials. The bottleneck isn't patients or investigators — it's sites. We unpack the arithmetic of the gap and what an organised, nationwide site network would actually change for sponsors.
Read the article
A single uncontrolled thaw can destroy years of RNA integrity. A walk through the redundancies — power, monitoring, alarms, aliquoting — that keep a biospecimen scientifically usable a decade after collection.
Read more
Inspection readiness is not a week of preparation — it's a documentation habit. The operating rhythm behind three consecutive years of DCGI audits with no major findings.
Read more
Broad consent, re-contact rights, withdrawal, de-identification. How to build a consent architecture that a donor understands today and an ethics committee still respects in 2036.
Read more
Feasibility to first-patient-first-visit in three weeks is achievable when contracting, ethics submission and staff certification run in parallel rather than in sequence. Here's the parallel plan.
Read more
An unannotated sample is a freezer occupant, not a research asset. Why clinical metadata — staging, treatment lines, outcomes — is the variable that decides a biobank's scientific value.
Read moreNo articles in this category yet — check back soon.
